EMA Withdrawn: Bortezomib Hospira (bortezomib) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA has withdrawn the European marketing authorization for Bortezomib Hospira (bortezomib) by Pfizer Europe MA EEIG, affecting treatment of multiple myeloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib Hospira (bortezomib)

Snippet

Status: Withdrawn. Therapeutic area: Multiple Myeloma. MAH: Pfizer Europe MA EEIG. Decision date: 16/05/2025